Showing results (1031-1040 of 5,663) with videos related to

Sort By:
Pageof 567
Lupus|June 10, 2024
The additional role of anti-nucleosome antibodies in the prediction of renal damage in systemic lupus erythematosus based on CSTAR (XXV)Yufang Ding, Yangzhong Zhou, Jiuliang Zhao, et al.
Lupus|June 11, 2024
Sustained depression of B cell counts in lupus nephritis after treatment with rituximab and/or belimumab is associated with fewer disease flaresDiane Zisa, Jeffrey Zhang-Sun, Paul J Christos, et al.
Lupus|June 11, 2024
Belimumab-induced periungual pyogenic granulomas: A case reportCecilia Beatrice Chighizola, Ilaria Suardi, Achille Marino, et al.
Lupus|June 17, 2024
Associations between TCA cycle plasma metabolites and fatigue in black females with systemic lupus erythematosus: An untargeted metabolomics pilot studyLaura P Kimble, Arezou Khosroshahi, Glenna S Brewster, et al.
Lupus|May 15, 2024
Uncommon toxic epidermal necrolysis -like presentation of cutaneous lupus erythematosus: A series of 6 casesVarun Rajagopal, Anupama Bains, Karthick Kannan, et al.
Lupus|August 26, 2023
Adherence patterns to medications and their association with subsequent hospitalization in adult Egyptian patients with systemic lupus erythematosusSamar Tharwat, Eman Ali Shaker
Lupus|October 20, 2023
Disease-modifying effect and long-term safety of belimumab in patients with systemic lupus erythematosus: A single-center retrospective studyTakehiro Nakai, Sho Fukui, Haruki Sawada, et al.
Lupus|October 3, 2023
Maternal and fetal health outcomes in systemic lupus erythematosus pregnancies in the Emirati population: A comparative studyHiba I Khogali, Ghada S M Al-Bluwi, Virgie Guy Pedo, et al.
Lupus|October 9, 2023
A single-center model for implementation of SLEDAI documentation adherence in childhood-onset systemic lupus erythematosus (cSLE)Meghan Corrigan Nelson, Colleen Mosley, Tonya Bennett, et al.
Lupus|September 27, 2023
Repeat kidney biopsy findings of lupus nephritis patients in clinical remission treated with Mycophenolate associated with Belimumab or Mycophenolate plus standard of care therapy. A "post-hoc" analysis of participants in the BLISS-LN and open label extension study belonging to a single centerAna Malvar, Valeria Alberton, Cecilia Recalde, et al.
Pageof 567